Applied Therapeutics completes merger and Nasdaq delisting move

An update from Applied Therapeutics ( (APLT) ) is now available.

On February 3, 2026, Applied Therapeutics completed a merger that triggered its decision to voluntarily delist its shares from the Nasdaq Stock Market and deregister them under the Securities Exchange Act of 1934, meaning its stock ceased trading on Nasdaq and the company plans to suspend its public reporting obligations. As part of the transaction, the existing board members and key officers resigned at the effective time of the merger, with James Harrison, formerly the sole director and president of the acquiring entity, becoming the sole director and president of Applied Therapeutics, and Andrea Reiner assuming the role of company secretary, marking a full shift of corporate control to the buyer’s leadership team.

The most recent analyst rating on (APLT) stock is a Sell with a $0.09 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.

Spark’s Take on APLT Stock

According to Spark, TipRanks’ AI Analyst, APLT is a Neutral.

The score is primarily weighed down by weak financial performance—large operating losses, persistent heavy cash burn, and negative equity—alongside strongly bearish technical signals (price below key moving averages and negative MACD). Valuation offers limited offset given ongoing losses (negative P/E) and no dividend yield data.

To see Spark’s full report on APLT stock, click here.

More about Applied Therapeutics

Applied Therapeutics operates in the biopharmaceutical industry, developing clinical-stage drugs targeting high unmet medical needs, with a focus on novel therapies for metabolic and neurological diseases, positioning itself within the specialty therapeutics segment of the healthcare market.

Average Trading Volume: 15,815,490

Technical Sentiment Signal: Sell

Current Market Cap: $14.83M

See more insights into APLT stock on TipRanks’ Stock Analysis page.